Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biolinerx Ltd (BLRX)

Biolinerx Ltd (BLRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,752
  • Shares Outstanding, K 7,478
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,450 K
  • 60-Month Beta 2.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.60
  • Number of Estimates 2
  • High Estimate -0.60
  • Low Estimate -0.60
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -1,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.68 +33.33%
on 07/07/20
2.51 -10.76%
on 07/31/20
+0.51 (+29.48%)
since 07/02/20
3-Month
1.53 +46.41%
on 06/15/20
2.51 -10.76%
on 07/31/20
+0.59 (+35.76%)
since 05/01/20
52-Week
1.06 +111.14%
on 03/18/20
4.14 -45.89%
on 08/05/19
-1.62 (-41.97%)
since 08/02/19

Most Recent Stories

More News
BioLineRx to Report Second Quarter 2020 Results on August 6, 2020

, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for...

BLRX : 2.24 (-1.32%)
BioLineRx (BLRX) to Report Q2 Earnings: What's in the Cards?

BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.

ALKS : 18.68 (+3.72%)
BMY : 59.10 (+0.75%)
BLRX : 2.24 (-1.32%)
ACAD : 43.27 (+4.09%)
Bet on Rising Price-to-Earnings With 5 Top Stocks

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

BLRX : 2.24 (-1.32%)
AVGR : 0.5578 (+25.04%)
PTI : 1.4900 (+1.36%)
VIVE : 0.5750 (+1.64%)
VCNX : 6.40 (+1.11%)
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher

Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

BLRX : 2.24 (-1.32%)
ACRS : 2.13 (-0.93%)
Pacira (PCRX) Provides Preliminary Results for Second Quarter

Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.

BLRX : 2.24 (-1.32%)
PCRX : 54.89 (+4.33%)
ATXI : 10.18 (+0.49%)
AMRX : 4.71 (+8.78%)
Acceleron (XLRN) in Focus: Stock Moves 5.3% Higher

Acceleron (XLRN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

BLRX : 2.24 (-1.32%)
XLRN : 105.30 (+6.18%)
Zogenix (ZGNX) in Focus: Stock Moves 7.6% Higher

Zogenix (ZGNX) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

BLRX : 2.24 (-1.32%)
ZGNX : 24.35 (+2.35%)
Onconova Initiates Phase I/IIa Study on Lung Cancer Candidate

Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.

BMY : 59.10 (+0.75%)
BLRX : 2.24 (-1.32%)
ONTX : 1.1400 (-0.87%)
AMRX : 4.71 (+8.78%)
Jazz's Aggressive Lung Cancer Drug Zepzelca Gets FDA Approval

FDA's accelerated approval to Jazz's (JAZZ) Zepzelca as a monotherapy for metastatic small cell lung cancer patients set to boost the company's oncology portfolio.

JAZZ : 111.93 (+3.40%)
BLRX : 2.24 (-1.32%)
BLCM : 7.13 (+6.26%)
ATNM : 0.6000 (+4.11%)
BioLineRx Announces $4.39 Million Registered Direct Offering

, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with...

BLRX : 2.24 (-1.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade BLRX with:

Business Summary

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040,...

See More

Key Turning Points

2nd Resistance Point 2.46
1st Resistance Point 2.35
Last Price 2.24
1st Support Level 2.15
2nd Support Level 2.07

See More

52-Week High 4.14
Fibonacci 61.8% 2.96
Fibonacci 50% 2.60
Fibonacci 38.2% 2.24
Last Price 2.24
52-Week Low 1.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar